BVXP
NEUTRALBioventix Plc Announces Director Dealing
The healthcare company announces a director has purchased additional shares.
Bioventix
1,700.50GBX
-4.20%
Market Cap
88.85M
Volume
18.57k
112% of avg
P/E Ratio
9.48
EPS (TTM)
179.3
Beta
0.63
Day Range
1,666.00p - 1,815.00p
52 Week Range
1,666.00p1,700.50p3,650.00p
1,700.50p
Upcoming Events
2026
Expected growth in troponin royalties
High Impact Event
June 30, 2032
Termination of Siemens troponin revenues
High Impact Event
BVXP
NEUTRALBioVentix Announces Change in Shareholding
The healthcare company has announced a change in its major shareholding structure.
BVXP
NEUTRALBioventix Publishes Annual Report and AGM Notice
The healthcare company has published its annual report and announced the date of its upcoming annual general meeting.
BVXP
NEUTRALBioventix Director Purchases Shares
The CEO and his wife have purchased additional shares in the healthcare company.
BVXP
NEUTRALBioventix Plc Announces Director Dealing
The healthcare company has announced that its Non-Executive Chairman has purchased additional shares in the company.
BVXP
NEUTRALBioventix Director Purchases Shares
The CFO of the biotechnology company has purchased a small number of shares.
BVXP
BADBioventix Reports Profit and Revenue Decline in Annual Results
The biotechnology firm reported a 3.6% revenue decline and a 4.8% drop in profit before tax. Facing headwinds in the Chinese market and pressure on core products, the company pins hopes on emerging neurology diagnostics opportunities.
BVXP
NEUTRALBioventix PLC Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
BVXP
NEUTRALBioventix Director Purchases Shares
The Chief Financial Officer of the biotechnology company has purchased a small number of shares.
BVXP
BADBioventix Raises Funds Through Discounted Share Placement
The healthcare company has announced a discounted equity raise, raising concerns about its financial health and future funding prospects.